Featured Tickers:
Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Aurinia Pharmaceuticals Inc. or Merus N.V. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Aurinia Pharmaceuticals Inc. and Merus N.V. compare based on key financial metrics to determine which better meets your investment needs.
About Aurinia Pharmaceuticals Inc. and Merus N.V.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Latest Biotechnology and Aurinia Pharmaceuticals Inc., Merus N.V. Stock News
As of November 19, 2025, Aurinia Pharmaceuticals Inc. had a $2.0 billion market capitalization, compared to the Biotechnology median of $200.4 million. Aurinia Pharmaceuticals Inc.’s stock is NA in 2025, NA in the previous five trading days and up 87.19% in the past year.
Currently, Aurinia Pharmaceuticals Inc.’s price-earnings ratio is 27.6. Aurinia Pharmaceuticals Inc.’s trailing 12-month revenue is $265.8 million with a 29.3% net profit margin. Year-over-year quarterly sales growth most recently was 8.4%. Analysts expect adjusted earnings to reach $0.782 per share for the current fiscal year. Aurinia Pharmaceuticals Inc. does not currently pay a dividend.
Currently, Merus N.V. does not have a price-earnings ratio. Merus N.V.’s trailing 12-month revenue is $56.6 million with a -673.3% net profit margin. Year-over-year quarterly sales growth most recently was 3.4%. There are no analysts providing consensus earnings estimates for the current fiscal year. Merus N.V. does not currently pay a dividend.
How We Compare Aurinia Pharmaceuticals Inc. and Merus N.V. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Aurinia Pharmaceuticals Inc. and Merus N.V.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions